Furthermore, clinical feature analysis results confirmed that the expression of SLC6A13 is affected by different clinical parameters of LIHC, especially in terms of tumor grade, gender differences, histological subtypes, and TP53 mutation status. This evidence concerns the gene SLC6A13 and neoplasm.